» Articles » PMID: 25270965

MICA SNPs and the NKG2D System in Virus-induced HCC

Overview
Journal J Gastroenterol
Specialty Gastroenterology
Date 2014 Oct 2
PMID 25270965
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) is one of the most frequent causes of cancer-related death globally. Above well-known risk factors for HCC development ranging from various toxins to diseases such as diabetes mellitus, chronic infection with hepatitis B virus and hepatitis C virus (HCV) poses the most serious threat, constituting the cause in more than 80 % of cases. In addition to the viral genes intensively investigated, the pathophysiological importance of host genetic factors has also been greatly and increasingly appreciated. Genome-wide association studies (GWAS) comprehensively search the host genome at the single-nucleotide level, and have successfully identified the genomic region associated with a whole variety of diseases. With respect to HCC, there have been reports from several groups on single nucleotide polymorphisms (SNPs) associated with hepatocarcinogenesis, among which was our GWAS discovering MHC class I polypeptide-related sequence A (MICA) as a susceptibility gene for HCV-induced HCC. MICA is a natural killer (NK) group 2D (NKG2D) ligand, whose interaction with NKG2D triggers NK cell-mediated cytotoxicity toward the target cells, and is a key molecule in tumor immune surveillance as its expression is induced on stressed cells such as transformed tumor cells for the detection by NK cells. In this review, the latest understanding of the MICA-NKG2D system in viral HCC, particularly focused on its antitumor properties and the involvement of MICA SNPs, is summarized, followed by a discussion of targets for state-of-the-art cancer immunotherapy with personalized medicine in view.

Citing Articles

Efficacy of measuring natural killer-activating receptor ligands to predict the pathogenesis of metabolic dysfunction-associated steatotic liver disease.

Arai J, Okumura A, Kimoto S, Sakamoto K, Kitada T, Kitano R Hepatol Int. 2025; .

PMID: 40085416 DOI: 10.1007/s12072-025-10800-y.


Integrated bioinformatics analysis and experimental validation to understand tryptophan metabolism-related genes in hepatocellular carcinoma.

Chen H, Sun W, Xie M, Li Z, Chen B, Zhang T J Cancer. 2024; 15(15):4879-4892.

PMID: 39132147 PMC: 11310871. DOI: 10.7150/jca.91306.


The Impact of interferon lambda 3 Polymorphism on Hepato-Cellular Carcinoma Progression in Hepatitis C Virus Patients: Treatment-Naïve and Experienced.

Abd Elrahman M, Ibrahim M, Khairy A, Yosry A, Zayed N, Tawefeek S Asian Pac J Cancer Prev. 2023; 24(1):215-221.

PMID: 36708570 PMC: 10152876. DOI: 10.31557/APJCP.2023.24.1.215.


The immunological role of ADAMs in the field of gastroenterological chronic inflammatory diseases and cancers: a review.

Arai J, Otoyama Y, Nozawa H, Kato N, Yoshida H Oncogene. 2022; 42(8):549-558.

PMID: 36572816 PMC: 9937921. DOI: 10.1038/s41388-022-02583-5.


Prognostic Role of Molecular and Imaging Biomarkers for Predicting Advanced Hepatocellular Carcinoma Treatment Efficacy.

Cerrito L, Ainora M, Mosoni C, Borriello R, Gasbarrini A, Zocco M Cancers (Basel). 2022; 14(19).

PMID: 36230569 PMC: 9564154. DOI: 10.3390/cancers14194647.


References
1.
Kim G, Mahoney M, Szydlo D, Mok T, Marshke R, Holen K . An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. Invest New Drugs. 2010; 30(1):387-94. PMC: 3896232. DOI: 10.1007/s10637-010-9532-1. View

2.
Lange C, Bibert S, Dufour J, Cellerai C, Cerny A, Heim M . Comparative genetic analyses point to HCP5 as susceptibility locus for HCV-associated hepatocellular carcinoma. J Hepatol. 2013; 59(3):504-9. DOI: 10.1016/j.jhep.2013.04.032. View

3.
Yu F, Liu H, Lee J, Liao M, Shih W . Hepatitis B virus X protein promotes cell migration by inducing matrix metalloproteinase-3. J Hepatol. 2005; 42(4):520-7. DOI: 10.1016/j.jhep.2004.11.031. View

4.
Zhang Z, Zhang S, Zou Z, Shi J, Zhao J, Fan R . Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients. Hepatology. 2011; 53(1):73-85. PMC: 3767982. DOI: 10.1002/hep.23977. View

5.
Sun D, Wang X, Zhang H, Deng L, Zhang Y . MMP9 mediates MICA shedding in human osteosarcomas. Cell Biol Int. 2010; 35(6):569-74. DOI: 10.1042/CBI20100431. View